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Adverse drug reactions caused by drug-drug interactions in cardiovascular 
disease patients: introduction of a simple prediction tool using electronic 
screening database items 
Objective: Cardiovascular disease (CVD) drugs have been frequently implicated in adverse 
drug reaction (ADR)-related hospitalisations. Drug-drug interactions (DDIs) are common 
preventable cause of ADRs, but the impact of DDIs in the CVD population has not been 
investigated. Hence, the primary aim of the study was to identify DDIs associated with 
ADRs in CVD patients at hospital admission. The second aim was to develop a simple tool 
to identify high-risk patients for DDI-related adverse event. 
Methods: An observational study was conducted on Cardiology ward of University 
Clinical Hospital Center. Data were obtained from medical charts. A clinical panel 
identified DDIs implicated in ADRs, using LexiInteract database and Drug Interaction 
Probability Score. Statistics were performed using PASW 22 (SPSS Inc.).  
Results: DDIs contributed to hospital admission with a total prevalence of 9.69%. DDI-
related ADRs affected mainly cardiac function (heart rate or rhythm, 41.07%); bleeding 
and effect on blood pressure were equally distributed (17.86%). Non-cardiovascular ADRs 
were found in 23.21% of DDIs. After the admission, 73% of the identified DDIs led to 
changes in prescription. Prediction ability of calculated DDI-adverse event probability 
scores was rated as good (AUC=0.80, p<0.001).  
Conclusions: CVD patients are highly exposed to adverse DDIs; about one in ten patients 
hospitalized with CVD might have a DDI contributing to the hospitalisation. Given the 
high prevalence of CVD, DDI-related harm might be significant burden worldwide. 
Identification of patients with high DDI-adverse event risk might ease the recognition of 
DDI-related harm and improve the use of electronic databases in clinical practice. 













Drug safety has become a public health issue, earning significant and wide interest at all levels 
of health care. 
1
 The benefit-risk ratio of a particular drug has become more complex to assess 
and interpret, due to an increased number of drugs in therapy in the ageing population, and the 
volume of knowledge about drug-drug and drug-disease interactions. 
2
 Besides its challenging 
aspect in achieving effective and safe therapy for an individual patient, drug-related harm 
substantially contribute to health care costs. 
3, 4
 An adverse drug reaction (ADR) is defined as 
“any response to a drug which is noxious and unintended, and which occurs at doses normally 
used in man for prophylaxis, diagnosis, or therapy of disease, or for the modification of 
physiological function”. 
5
 ADRs can occur in appropriately prescribed, dispensed or 
administered drugs (considered as nonpreventable), but they can also be caused by drug-drug 
interactions (DDIs) when an altered drug effect emerge in a presence of the precipitant drug.  
DDIs are identified as a preventable cause of ADRs, irrespective of the study setting. 
6, 7
 DDIs 
accounted for 16.6-49% of ADR-related hospitalisations 
7-10
, and were present in about 44% of 
cases reported as drug-related deaths in a university hospital. 
11
 Epidemiological data derived 
from meta-analysis estimated the total median prevalence rate of DDI-related hospital 
admissions to about 1.1%. 
7
 However, it was reported that the low incidence of DDIs might be 
an indication of a lack of understanding and recognition of DDIs. 
12
 Other authors also stated 
that the true extent of DDI-related harm is not well established. 
13, 14
 Nevertheless, both 
researchers and health professionals agree upon the need for generating new evidence on DDIs, 
to reach improvements in drug safety. 
15, 16
 
Drugs used for cardiovascular disease (CVD) lead the list of ADRs and DDIs causative agents, 
identified both through a detailed medical charts exploration in epidemiological research, as well 
as through spontaneous reporting. A comprehensive review by Al Hamid et al. reported that 










with a median of 33.9% (interquartile range 19.9–58.6%). 
17
  Furthermore, a large French study 
on more than 6.9 million outpatient dispensings revealed dominant involvement of CVD drugs 
in DDIs: four out of five most represented contraindicated drug pairs, and all of the five most 
represented discommended drug pairs involved cardiovascular drugs. 
18
 In addition, patients 
with CVD are at higher risk and exposure to DDIs because of the multiple medications, as well 
as the administration of drugs with narrow therapeutic index, such as warfarin or digoxin. 
1, 19
 
Prescribing of several drugs is common in CVD, which is the main reason for the reported high 
prevalence of potential DDIs: 91.1-93.7% of hospitalised cardiac patients had at least one 
potential clinically significant DDI regardless of the type of severity. 
20, 21
 The DDI-related harm 
in general, as well as their impact on hospital admissions in the population of CVD patients has 
not been well examined.  Studies carried out in CVD patients investigated iatrogenic adverse 
events emerging during hospitalization in the coronary care unit, assessing both those resulting 
from medical procedures and the medication use. 
22, 23
 Others provided general prevalence rates 
of drug-related problems in CVD patients during hospital stay 
24
, or DDIs were assessed only in 
the cohort of heart failure patients. 
25, 26
Another issue in assessing DDIs impact is the causality 
assessment. The only available tool so far is a 10-item Drug Interaction Probability Scale 
(DIPS), proposed by Horn and colleagues. 
27
 The DIPS purpose is to ease the judgement of the 
contributory role of a potential DDI to a specific patient outcome, in comparison to other 
potential causes. Electronic databases can be easily applied in DDIs screening, giving the 
opportunity to quickly assess potential problems in patients therapy. However, significant 
override rates have been reported for DDIs alerts (up to 72.8 %), due to alert fatigue caused by a 
high frequency of generated alerts in computerized physician order systems, or intended 
prescriptions. 
28
 Therefore, the primary aim of the study was to identify DDI-related ADRs, 
suspected to cause or contribute to the clinical findings obtained at the moment of hospital 
admission in CVD patients. The second aim was to develop a simple prediction tool based on 
existing LexiInteract
®
 monograph items 
29










the occurrence of an adverse event due to DDI. 
Methods 
Study design and setting 
An analytical observational study was conducted investigating consecutive patient admissions 
on Cardiology ward of University Clinical Hospital Center Bežanijska Kosa, Belgrade, Serbia. 
University Center is a state-owned, non-profit, general hospital with 400 beds. It is located in the 
capital of Serbia, providing care to the patients from Belgrade as well as to more complex 
patients from the other parts of Serbia, who needed more specific diagnostic or interventional 
procedures. Cardiology ward is a department of Internal medicine Clinic, which receives adults 
with acute and chronic cardiovascular disorders for admission as well as for outpatient 
examination and treatment. The Ethics committee of the University Clinical Hospital Center 
Bežanijska Kosa approved this study (No 222/3).  
Patient data 
Patients demographic and clinical data were obtained from medical charts. All patients having 
complete data, including demographic data such as age and gender, medical history, reason for 
hospitalisation, clinical and laboratory parameters noted at the admission, as well as the therapy 
used before and during hospitalisation were included in the study. Additionally, in case of noted 
physician suspicion on the adherence, those patients were excluded from the study. We collected 
data on complete therapy used in the outpatient setting prior to admission to hospital (including 
medications, supplements, and OTC products), which were used at least a month before the 










Identification of potential DDIs 
Screening for potential DDIs was performed using LexiInteract electronic database (Lexi-Comp, 
Inc., Hudson, Ohio). 
29
 Risk rating classes X, D, and C were considered as potential clinically 
significant DDIs (risk rating scale presented in Table 1). Additionally, LexiInteract monograph 
was used to extract data on proposed mechanism, severity and reliability of a DDI. Severity 
indicators include: minor (effects would be considered tolerable in most cases - no need for 
medical intervention); moderate (medical intervention needed to treat effects; effects do not 
meet criteria for major); and major (effects may result in death, hospitalization, permanent 
injury, or therapeutic failure). LexiInteract gives a brief presentation of published data referring 
to the observed/presumed interaction in the Discussion section of DDI monograph, with medical 
literature citations. Depending on the type and quality of published evidence for a certain DDI, 
reliability was defined as poor, fair, good, or excellent. 
Table 1 
Identification of ADRs associated with DDIs 
In the next step, a clinical panel consisted of a cardiologist (22 years clinical experience 
as a specialist in internal medicine, 8 years clinical experience as a subspecialist in cardiology), a 
clinical pharmacist (7 years clinical experience, with 2 years on cardiology ward), and a PhD 
student in clinical pharmacy (1 year experience on cardiology ward) reviewed the patients 
medical charts. Data on clinical findings reported at the admission were thoroughly discussed, 
estimating the impact of potential DDIs on patients clinical and laboratory parameters. Causality 
between the adverse event and the suspected DDI were assessed using Drug Interaction 
Probability Scale (DIPS) introduced by Horn et al. The Naranjo scale, which estimates the 
probability that an ADR was caused by a single drug, was used as a basis for the DIPS. 
27
 The 
application of the DIPS to a potential DDI requires knowledge of the pharmacologic, 










a series of 10 questions to assess the probability that a causal relationship exists between an 
event observed in a patient and the coadministration of two drugs. The scale comprises the 
evaluation of DDI in terms of: (1) previous credible reports; consistency with the known 
properties of (2) precipitant or (3) object drug; (4) time course; (5) dechallenge; (6) rechallenge; 
(7) alternative causes; (8) concentration of object drug in blood or other fluids; (9) other 
objective evidence, other than drug concentration; (10) change in the interaction with precipitant 
drug dose change. Each question is answered with a "yes," "no," or "unknown/not applicable" 
response, with assigned numeric score for each question. The total score is used to estimate the 
probability that the interaction is causally related to the patient event. In our study, potential 
DDIs with the estimated at least probable causality (DIPS score ≥2) with the adverse event 
reported in the medical charts, and upon the agreement of all the panelists, were coded as  
adverse DDIs.  
Statistical analysis 
Descriptive and inferential statistics were performed using PASW 22 (SPSS Inc., Chicago, IL, 
USA). Categorical variables were reported as the number of patients with percentage, ordinal as 
the median value with interquartile and total range, and continuous as the mean value ± standard 
deviation with total range. Chi-square (or Fisher’s exact test, where appropriate) and Mann 
Whitney tests were used to assess the difference in patients characteristics between groups with 
and without DDI-related ADR. Binary logistic regression was used to investigate the factors 
associated with the occurrence of DDIs involved in ADRs. Odds ratios, both crude and adjusted 
for the number of drugs, were reported. A two-tailed p value <0.05 was considered statistically 
significant. Estimated odds ratios were further used as the scoring points in calculating the DDI-
adverse event (DDI-AE) probability score. DDI-AE score is based on LexiInteract monographs, 
which reference to published studies on DDIs (in vitro, animal or human studies, where 










certain extent of drug-adverse effect relationship might be suspected from the LexiInteract 
monograph, a causality in an individual patient is assumed to be  assessed after the calculation of 
DDI-AE score, i.e. only in patients with calculated high cumulative risk of DDI manifestation. 
Therefore the score was named for the term „event“. Diagnostic accuracy of the DDI-AE 
probability score was tested using receiver operating characteristic (ROC) analyses. Performance 
was defined as acceptable when AUC=0.70-0.79, excellent when AUC=0.80-0.89, and AUC 













A total of 421 consecutive medical records were retrieved, where 54 patients (12.8%) had 
incomplete data on therapy used before the admission, and 16 patients (3.8%) were marked as 
non-adherent, according to open-form notes made by the accountable physician at the admission. 
Finally, a total of 2089 drug prescriptions were found in 351 patients at the moment of 
admission. The median number of drugs per patient was 6 (interquartile range 4-8, total range 1-
15). Polypharmacy (≥5 drugs) was present in 68.95% and ≥10 drugs were found in 8.83% of 
patients. Patients were mainly older (aged ≥65 years; 254, 72.36%), and 48.43% (170) were 
females. Table 2 presents the demographic and clinical characteristics of the study population. 
Table 2 
Potential DDIs 
Given the number of drugs, a total of 5908 drug pairs were tested for potential DDIs. 
Potential clinically significant DDIs (X, D and C class) were identified in 1606 drug pairs 
(27.18%). The vast majority of drug pairs were in C class (1452, 90.41%), 143 (8.90%) DDIs 
were in D class, and only 11 (0.68%) were in X class, accordingly to risk rating. The total 
prevalence of potential clinically significant DDIs was estimated to 83.19% (292 patients). 
 
Adverse drug reactions associated with DDIs 
The clinical panel identified a total of 56 drug pairs being suspected to cause or 
contribute to clinical findings obtained at the moment of hospital admission. According to 
LexiInteract, those adverse interacting drug pairs actually corresponded to 30 unique DDIs 
implicated in ADRs. ADRs attributed to DDIs were identified in 34 patients, with a total 
prevalence of 9.69% in the studied population. In patients having at least one potential DDI at 










adverse DDIs were C class (40 DDIs,71.43%), followed by D class (14 DDIs,25%), and only 2 
DDIs (3.57%) were assigned an X class risk rating. Severity, as graded by LexiInteract was 
assessed as moderate in 35 DDIs (62.5%), and major in 21 DDIs (37.5%). Regarding DDI 
reliability stated in the LexiInteract monograph, there were only 7 DDIs (12.5%) reported as 
excellent, 12 (21.43%) reported as good, and 37 (66.07%) reported as fair based on the 
published reports. In total, 41 different drugs (INN) from seven ATC classes were involved in 
actual DDI-related ADRs. The highest frequency was observed for cardiovascular system drugs 
(ATC class C, 46 out of 112), with mainly involved ACE inhibitors (10 times). Table 3 shows 
the frequency of ATC classes with class members implicated in DDI-related ADRs.  
Table 3 
Detailed data on identified ADRs attributed to DDIs are given in Table 4. ADRs most 
frequently involved effect on cardiac function (41.07%) –tachycardia or irregular heart rhythm 
(N=20, 35.7%), and much less frequent bradycardia (N=3, 5.36%). Bleeding and effect on blood 
pressure were equally distributed (N=10, 17.86%), whereas hypotension was more frequent, than 
hypertension. Non-cardiovascular events were found in 23.21% of cases, including 
hyperkalemia, low red cell count, elevated liver enzymes, epigastric pain, and hyperthermia. 
After the admission, 14 (25%) DDIs remained during the hospitalisation without dose 
adjustments of either object or precipitant drug, in one case (2%) the dose of object drug was 
decreased, and 41 (73%) of identified DDIs led to changes in prescription. 
Table 4 
Calculation of DDI-AE probability score 
Among patients characteristics, the prevalence of adverse DDIs was not associated with 
gender or older age (Table 5). Statistical significance was shown only for the number of drugs, 










DDIs, such as risk rating class, severity and the underlying DDI mechanism, were significantly 
associated with the adverse outcome of DDIs in the studied population (Table 5). Odds ratios 
presented in Table 5, were used to calculate the DDI-AE probability score. Items with the 
proposed points are presented in Table 6. Two DDI-AE probability scores were tested, DDI-AE 




Prediction ability of DDI-AE probability score 
Performance of DDI-AE probability scores was rated as good, with the results 
comparatively presented in Table 7. DDI-AE 1 score differed significantly between patients with 
and without DDI-related ADR at admission: median 9.00 [IQR 7.75-11], and 6 [IQR 0-7] 
(p<0.001), respectively. Median values for DDI-AE 2 score were 21.60 [IQR 15.80-23.70] in 
patients with DDI-related ADR, compared to 13 [IQR 5.60-18.20] (p<0.001) in patients without 
adverse DDI implicated in admission. ROC analyses to evaluate the diagnostic accuracy of DDI-
AE 1 and DDI-AE 2 probability score yielded an AUC of 0.800 (95% CI 0.744-0.856) and 0.811 
(0.750-0.872), respectively. In spite of slightly lower AUC value, DDI-AE 1 score (not 
including the number of drugs in the score estimation) showed somewhat better sensitivity and 
specificity features. The suggested cut-off of 7 points for DDI-AE score 1 demonstrated 76.5% 
sensitivity and 77.9% specificity in predicting the occurrence of adverse drug event given the 
characteristics for potential DDIs stated in the LexiInteract monograph. 











To our knowledge, the prevalence of DDI-related hospitalisations and the identification 
of adverse DDIs have not been previously investigated in CVD patients. Our study revealed the 
prevalence of DDI-related ADRs in 9.69% of CVD admissions to the cardiology service of our 
hospital.  ADRs related to DDIs were uncommon and usually not major, but it is likely that in 
non-academic hospitals and non-specialty services the frequency may be substantially higher. In 
our study, adverse DDIs mainly affected cardiac function (41.07%) – causing tachycardia or 
irregular heart rhythm (35.7%), and much less frequent bradycardia (5.36%). Bleeding and 
effect on blood pressure were equally distributed (17.86%), whereas non-cardiovascular events 
were found in 23.21% of adverse DDIs. Gastrointestinal tract bleeding (33-40%), hyper- and 
hypotension (18%), and cardiac rhythm disturbances (18-30%) were identified to be the most 
frequent adverse events resulting from DDIs. 
7, 12
 The study setting might hold the explanation 
for the discrepancy in gastrointestinal tract bleeding frequency, as those patients might be more 
frequently admitted through emergency department or hospitalised at gastroenterology ward. 
Interestingly, the proportion of patients with liver or renal disease in anamnesis was 
significantly lower in the group with adverse DDI (Table 2). It might reflect the increased and 
existing awareness on drugs prescribing in patients with known decrease in liver or renal 
function, as a well known risk of ADRs occurrence. Still, harmful drug combinations have been 
identified in about 10% of CVD patients. Nevertheless, a higher prevalence of adverse DDIs 
might be expected in CVD patients, due to interacting potential of CVD drugs. 
1
 Additionally, it 
was reported CVD itself might increase the risk of ADRs, by altering renal and hepatic 
perfusion, or causing hypoxia. 
31
 Hence, drug elimination and tolerability may be further 
compromised in CVD patients, irrespective of other risk factors. 
31, 32
 Other studies dealing with 
cardiac inpatients reported ADR occurrence in 34% of patients during hospital stay 
33
, whereas 












 Further, the wide variety of non-CVD drugs involved in DDIs were identified in our 
study, which assert the benefit of using DDI screening tools. Cardiologists are certainly well 
trained for CVD drugs and the expected effect of their concomitant use. However, drugs used in 
other therapeutic areas such as neurology, mental disease, respiratory disease, and urogenital 
disease, may have quite specific pharmacokinetic and pharmacodynamic and PD characteristics, 
which certainly require an electronic base support in assessing drugs interacting potential. It was 
confirmed that potential DDIs arise more often as a result of prescriptions from multiple 




Previous studies underlined that DDIs represent a real problem in clinical practice. 
6
 The 
main strategy for reducing DDIs is to use electronic decision support tools, which usually 
present DDIs as interruptive alerts. 
36
 Inevitably, alert fatigue and high rates of alert override are 
well-recognized consequences of receiving a high volume of DDI alerts. The issues of electronic 
alert fatigue and override rates were briefly described in the literature 
28, 37
, carrying the risk that 
prescribers may miss warnings of potentially serious adverse events. 
36
 The most frequently 
proposed strategy to combat alert fatigue is to reduce the total number of DDI alerts, by 
elimination of minor and/or moderate DDIs. 
36, 38, 39
 However, our study demonstrated that the 
majority of adverse DDIs were classified as C class (about 71%), attributed the lowest risk rating 
among all potential clinically significant DDIs, which is highly expected to be neglected in most 
of the DDI alerts. In addition, severity was graded as moderate in 62.5% and 37.5% of adverse 
DDIs. Given the high prevalence of potential clinically significant DDIs with 83%, other 
strategies have to be employed to deal with the alert fatigue in CVD patient population. We 
aimed to develop DDI-AE probability score to decrease the possibility for alert overrides 
through presenting a cumulative risk of DDIs, “displaying” only high-risk patients during the 










already incorporated in the LexiInteract monograph. Thus, the proposed score could be easily 
calculated as an add-on feature in the LexiInteract database. Although the number of drugs have 
been independent risk indicator for adverse DDI occurrence, better results were obtained for 
DDI-AE 1 score (cut-off value ≥7 points). Furthermore, a statistically significant higher median 
values for both DDI-AE 1 and DDI-AE 2 score were found in patients with adverse DDI, 
reflecting the possible additive or synergistic risk of multiple DDIs, in causing adverse outcome. 
The LexiInteract monograph denotes interacting/noninteracting members of a specific 
pharmacological group, giving the opportunity to improve patient’s therapy through avoiding 
potentially harmful DDIs. Furthermore, medical charts review presents significant workload for 
clinicians, to search for the evidence and occurrence of DDIs. 
40
 That is one of the main reason 
why DDI-related outcomes are still underinvestigated and underreported. Nowadays, different 
data mining strategies are being developed in identifying ADRs and DDI-related ADRs, to get 
closer to their real burden. 
41, 42
 Validation of the DDI-AE probability score is certainly needed 
in a larger population, however, the idea of stratifying patients according to DDI-related risk 
might ease future research, as well as the clinical practice. 
General recommendations for future research to improve DDI alerts have been given. 
One of them is a requirement to determine frequencies and clinical consequences of DDIs. 
43
 In 
line with that, the main strength of the study is the identification of adverse DDIs that caused or 
contributed to hospital admission in patients with CVD.  Detailed data at the admission and 
during the hospital stay were collected, which enabled comprehensive evaluation of adverse 
DDIs. On the other hand, our results are derived from 351 patient sample, which is the main 
limitation of the study. DDIs were underreported in this population, nevertheless, due to the 
number and nature of drugs used in CVD therapy, a higher risk might be expected. Lack of 
information in this area can easily result in over, as well as underestimation of the clinical 
consequences of DDIs. 
12










DDIs should be interpreted with caution due to small sample size. It has been recognized that the 
studies with a larger sample size showed low incidences and studies with a smaller size showed 
high incidences of adverse outcomes due to DDIs. Results from studies with a smaller sample 
size have a larger standard error, and outliers to higher numbers occur more often, wrongly 
presenting a higher incidence. Further, it is possible that in the smaller studies medication 
histories were studied in more detail than in the larger ones, and were therefore more readily 
able to recognise adverse patient outcomes due to DDIs. On the other hand, this may indicate 
that the percentages found in the larger studies are an underestimation of the true risk.
12
 It was 
also confirmed that a higher rates for adverse events have been found if active strategy was 
applied in data acquisition, compared to spontaneous reporting, which was the case in our 
research. 
44
 Moreover, this is a single-center study exploring the outcomes of the patients 
admitted to the academic hospital ward. It is likely that the reported results might be 
unrepresentative for other settings, such as non-academic, non-speciality or outpatient setting. 
Therefore, the proposed tool for identification of high-risk patients needs to be tested and 
validated in other settings or in other populations. Further research is needed in the larger sample 
to obtain the generalizability of the findings, and to improve prospective risk measures to deal 
with DDI-related adverse therapy outcomes. 
Conclusions 
Our study revealed significant burden of DDIs-related ADRs in CVD admissions to the 
cardiology service of our hospital. Generally, about one in ten patients hospitalized with CVD 
might have a DDI contributing to the hospitalisation. Given the high prevalence of CVD, DDI-
related harm might be significant burden worldwide. Electronic databases can be easily applied 
in predicting and preventing DDIs, but further improvements have been advocated to increase 
the quality and acceptance rates of DDI alerts. Identification of patients with high cumulative 









electronic databases in clinical practice. 
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Table 1. Drug-drug interactions risk rating scale according to the LexiInteract database 
Risk Rating Action Description 
A No Interaction Data have not demonstrated either pharmacodynamic or 
pharmacokinetic interactions between the specified agents. 
B No action needed Data demonstrate that the specified agents may interact 
with each other, but there is little to no evidence of clinical 
concern resulting from their concomitant use. 
C Monitor therapy Data demonstrate that the specified agents may interact 
with each other in a clinically significant manner. The 
benefits of concomitant use usually outweigh the risks. An 
appropriate monitoring plan should be implemented to 
identify potential negative effects. Dosage adjustments of 
one or both agents may be needed in a minority of patients. 
D Modify regimen Data demonstrate that the two medications may interact 
with each other in a clinically significant manner. A 
patient-specific assessment must be conducted to 
determine whether the benefits of concomitant therapy 
outweigh the risks. Specific actions must be taken in order 
to realize the benefits and/or minimize the toxicity - 
aggressive monitoring, empiric dosage changes, choosing 
alternative agents. 
X Avoid combination Data demonstrate that the specified agents may interact 
with each other in a clinically significant manner. The risks 
associated with concomitant use of these agents usually 












Table 2. Demographic and clinical characteristics of the study population 
 ADR attributed to DDI  
 Yes (N=34) No (N=317) p value 
 number of patients (%) number of patients (%)  
Gender, female 11 (32.35) 157 (49.53) 0.211 
Age, years    
mean ± S.D., total range 72.18 ± 11.05, 49-89 69.80 ± 9.98, 29-88 0.194 
≥65 24 (70.59) 230 (72.56) 0.807 
Number of drugs    
median [IQR], total range 8 [6-9.25], 5-15 6 [4-7], 1-14 <0.001 
≥5 34 (100) 208 (65.62) <0.001 
≥10 8 (23.53) 23 (7.26) 0.005 
Charlson comorbidity index    
median [IQR], total range 3 [2-4.25], 0-6 3 [2-4], 0-8 0.346 
mean ± S.D. 3.21 ± 1.59 2.97 ± 1.63 0.425 
Length of stay, days    
mean ± S.D., total range 10.65 ± 9.59, 2-54 9.40 ± 5.73, 1-42 0.266 
Clinical diagnosis    
heart failure 17 (50) 130 (41.01) 0.313 
angina pectoris 7 (20.59) 101 (31.86) 0.176 
hypertension 18 (52.94) 218 (68.77) 0.062 
arrhythmia 20 (58.82) 148 (46.69) 0.178 
myocardial infarction in anamnesis 3 (8.82) 39 (12.30) 0.552 
cerebral infarction in anamnesis 3 (8.82) 17 (5.36) 0.427 
diabetes mellitus 10 (29.41) 90 (28.39) 0.900 
respiratory disease 5 (14.71) 25 (7.89) 0.192 
endocrine disease, excluding diabetes 2 (5.88) 16 (5.05) 0.834 
gastrointestinal disease 3 (8.82) 18 (5.68) 0.442 
renal disease 1 (2.94) 24 (7.57) 0.492 
liver disease 0 10 (3.15) 0.607 
    
Clinical parameters at admission 
mean ± S.D. 
   
heart rate 88.53 ± 27.7 88.9 ± 23.9 0.749 
systolic blood pressure 132.06 ± 19.07 140.28 ± 24.23 0.057 
diastolic blood pressure 77.79 ± 14.57 84.43 ± 13.79 0.008 
    
Reason for admission    
heart failure 18 (52.94) 127 (40.06) 0.160 
arrhythmia 7 (20.59) 56 (17.67) 0.692 
hypertension 1 (2.94) 45 (14.20) 0.065 
angina pectoris 0 40 (12.62) 0.021 
ADR – adverse drug reaction; DDI – drug-drug interaction; S.D. – standard deviation; IQR – 
interquartile range; risk rating C - Monitor therapy; risk rating D - Consider therapy 










Table 3. Drug classes implicated in adverse drug-drug interactions  
Drug class Frequency (%) 
Cardiovascular system 46 (41.07) 
ACE inhibitors 10 (8.93) 
Aldosterone antagonists 8 (7.14) 
Antiarrhythmics, class III 6 (5.36) 
Digitalis glycosides 5 (4.46) 
Antiarrhythmics, class Ic 3 (2.68) 
Alpha and beta blocking agents 3 (2.68) 
HMG CoA reductase inhibitors 3 (2.68) 
High-ceiling diuretics, sulfonamides 2 (1.79) 
Peripheral vasodilatators, purine derivatives 2 (1.79) 
Calcium channel blockers, dihydropyridine derivatives 2 (1.79) 
Organic nitrates 1 (0.89) 
Beta blocking agents, selective 1 (0.89) 
Respiratory system 27 (24.11) 
Selective beta-2-adrenoreceptor agonists 15 (13.39) 
Xanthines 8 (7.14) 
Anticholinergics, inhalations 4 (3.57) 
Blood and blood forming organs 17 (15.18) 
Platelet aggregation inhibitors excl. Heparin 9 (8.04) 
Vitamin K antagonists 8 (7.14) 
Nervous system 14 (12.50) 
Barbiturates and derivatives 3 (2.68) 
Antipsychotics 3 (2.68) 
Analgesics and antipyretics, pyrazolones 2 (1.79) 
Benzodiazepine derivatives 2 (1.79) 
Antiepileptics, carboxamide derivatives 1 (0.89) 
Anti-Parkinson drugs, dopa and dopa derivatives 1 (0.89) 
Selective serotonin reuptake inhibitors 1 (0.89) 
Other antidepressants 1 (0.89) 
Antiinfectives for systemic use 4 (3.57) 
Macrolides 4 (3.57) 
Musculo-skeletal system 3 (2.68) 
Antigout preparations, preparations inhibiting uric acid production 3 (2.68) 
Genito urinary system and sex hormones 1 (0.89) 
Drugs used in benign prostatic hypertrophy, alpha-adrenoreceptor 
antagonists 
1 (0.89) 











Table 4. Adverse drug reactions attributed to drug-drug interactions identified at the hospital 
admission 
Adverse drug reactions 
DDIs Patient management 





Heart rate / rhythm (23)     
tachycardia, irregular heart 
rhythm 
 
   
aminophylline + 
amiodarone 
monitor for toxic effects of 
theophylline derivatives 












monitor for increased effects 
of sympathomimetics (eg, 
blood pressure, heart rate) 















monitor for increased serum 
concentrations and toxic 
effects of cardiac glycosides 
PK (P-gp, 
metabolism 




digoxin + erythromycin PK (P-gp, 
metabolism 






monitor closely for adverse 
cardiovascular effects of 
salmeterol (e.g., increased 









monitor for QTc interval 
prolongation and ventricular 
arrhythmias. Patients with 
other risk factors (eg, older 
age, female sex, bradycardia, 
hypokalemia, 
hypomagnesemia, heart 
disease, and higher drug 








fenoterol + salbutamol monitor for increased effects 
of sympathomimetics (eg, 
blood pressure, heart rate) 
PD C, Moderate, 
Fair 
1 





monitor for additive 
anticholinergic effects;  
monitor for additive CNS-
depressant effects 





avoid concurrent use of 
ipratropium with any other 
drugs that have 
anticholinergic properties. If 
such combinations can not be 
avoided, monitor patients 
closely for evidence of 
anticholinergic-related 
toxicities (e.g., urinary 
retention, constipation, 
tachycardia, dry mouth) 



















salmeterol + verapamil monitor closely for adverse 
cardiovascular effects of 
salmeterol (e.g., increased 







bradycardia     
amiodarone + carvedilol monitor for increased signs 
and symptoms of bradycardia 
with beta-blockers; atenolol 
interact in the smaller degree 
with amiodarone 
PK (metabolism 




carvediol + digoxin monitor for bradycardia or 
heart block, as well as 
potential increases in digoxin 
concentration 





monitor closely for signs or 
symptoms of digoxin toxicity. 
Additional monitoring of 
digoxin concentrations may 
also be warranted, but 
spironolactone and its 
metabolites may interfere 
with many different 
commerical digoxin assays 
PK (unknown) C, Moderate, 
Fair 
1 
Bleeding (10)     
aspirin + vitamin K 
antagonist 
monitor for increased signs 
and symptoms of bleeding  
PD D, Major, 
Excellent 
3 
aspirin + clopidogrel PD C, Moderate, 
Fair 
2 
amiodarone + vitamin K 
antagonist 
PK (metabolism) / 
PD indirect 
D, Major, Good 2 
clopidogrel + vitamin K 
antagonist 
PD C, Moderate, 
Fair 
2 
simvastatin + warfarin monitor for increased effects 
of oral anticoagulants if an 
HMG-CoA reductase 
inhibitor is initiated/dose 
increased. Dosage 
adjustments of the 
anticoagulant may be needed 
PK (metabolism) C, Moderate, 
Good 
1 
Blood pressure (10)     
hypertension     
amlodipine + 
carbamazepine 
consider alternatives to 
dihydropyridine calcium 
channel blockers. Monitor for 
reduced therapeutic effects of 
the calcium channel blocker. 




D, Major, Fair 1 
amlodipine + 
phenobarbitone 
consider an alternative in 
order to avoid therapeutic 










D, Major, Fair 1 
enalapril + metamizole special caution is needed in 
chronic heart failure patients, 
to avoid the potential negative 
consequences of concomitant 












NSAID therapy (fluid 
accumulation/edema). 
Monitor for decreased 
therapeutic effects of ACE 
inhibitor  
hypotension     
benserazide/levodopa + 
furosemide 
increased risk for 
symptomatic postural 
hypotension. Advise patients 
to minimize the risk of 
dizziness or falls  





monitor for additive CNS-
depressant effects.  Such 
effects may include, but are 
not limited to, ataxia, 
confusion, drowsiness, 
respiratory depression, and 
weakness 
PD C, Moderate, 
Good 
1 
carvediol + fluoxetine consider an alternative to 
avoid toxicity of the 
carvedilol. Some 
combinations are specifically 
contraindicated by 
manufacturers. Please review 








monitor blood pressure 
closely and advise patients of 
the possibility for enhanced 
blood pressure lowering 





PD C, Moderate, 
Fair 
1 
metoprolol + tamsulosin monitor closely for additive 
hypotensive effects  
PD C, Moderate, 
Fair 
1 
Hyperkalemia (6)     
enalapril + 
spironolactone 
monitor for increased 
incidence of hyperkalemia 
PD C, Major, Good 2 
fosinopril + 
spironolactone 
PD C, Major, Good 3 
metamizole + 
spironolactone 
monitor blood pressure and 
potassium concentrations 
closely 
PD C, Major, Fair 1 
Low red blood cells count 
(3) 
 
   
allopurinol + captopril if allopurinol must be used in 
an ACE inhibitor patient, 
monitor for evidence of 
hypersensitivity reactions  
unknown D, Major, Fair 1 
allopurinol + fosinopril unknown D, Major, Fair 1 
allopurinol + lisinopril unknown D, Major, Fair 1 
     
Elevated liver enzymes 
(AST and ALT) (2) 
 
   
amiodarone + 
simvastatin  
consider using pravastatin; 
limit the simvastatin dose to 
20 mg daily and monitor for 
evidence of simvastatin 
toxicities (eg, myalgia, liver 




D, Major, Good 2 
Epigastric pain (1)     
digoxin+spironolactone monitor closely for signs or 
symptoms of digoxin toxicity. 
Additional monitoring of 
digoxin concentrations may 
also be warranted, but 













PK – pharmacokinetic; PD - pharmacodynamic; risk rating C - Monitor therapy; risk rating D - 
Consider therapy modification; risk rating X - Avoid combination; AST - aspartate 
aminotransferase; ALT - alanine aminotransferase 
  
spironolactone and its 
metabolites may interfere 
with many different 
commerical digoxin assays 
Hyperthermia (1)     
clozapine + venlafaxine
  
monitor patients extra closely 
for evidence of serotonin 
toxicity (e.g., mental status 
changes, autonomic 
instability, and neuromuscular 
hyperactivity) or neuroleptic 
malignant syndrome (e.g., 
hyperthermia, muscle rigidity, 
autonomic dysfunction) 












Table 5. Factors associated with adverse drug-drug interactions 







Gender, male 1.59 (0.77-3.27) 0.214 1.21 (0.56-2.61) 0.634 
Age ≥65 years 0.91 (0.42-1.97) 0.807 0.57 (0.24-1.34) 0.195 
Number of drugs 1.42 (1.23-1.63) <0.001 -  
Charlson comorbidity index 1.09 (0.88-1.35) 0.424 0.76 (0.58-1.00) 0.052 
Clinical diagnosis     
Heart failure  1.44 (0.71-2.92) 0.315 0.84 (0.39-1.82) 0.653 
Angina pectoris  0.55 (0.23-1.32) 0.181 0.36 (0.14-0.91) 0.030 
Diabetes mellitus 1.05 (0.48-2.29) 0.900 0.63 (0.27-1.47) 0.284 
Hypertension 0.51 (0.25-1.04) 0.065 0.46 (0.21-0.99) 0.047 
Arrhythmia 1.63 (0.80-3.34) 0.181 1.63 (0.76-3.49) 0.205 
Respiratory disease 2.01 (0.72-5.66) 0.184 1.02 (0.32-3.28) 0.978 
     
Reason for admission     
Heart failure 1.66 (0.81-3.37) 0.164 1.00 (0.46-2.18) 0.993 
Arrhythmia 1.19 (0.49-2.88) 0.692 2.10 (0.81-5.46) 0.128 
Hypertension 0.18 (0.02-1.36) 0.096 0.30 (0.04-2.28) 0.243 
     
Potential DDIs characteristics     
risk rating     
X 7.57 (1.62-35.39) 0.010 2.35 (0.41-13.43) 0.338 
D 6.13 (2.89-12.98) <0.001 2.92 (1.24-6.89) 0.015 
C -    
number of C >2 9.17 (2.75-30.59) <0.001 3.43 (0.90-13.15) 0.072 
severity     
major 3.92 (1.86-8.29) <0.001 2.69 (1.20-6.02) 0.017 
moderate 2.14 (1.04-4.39) 0.038 1.32 (0.62-2.83) 0.476 
reliability     
excellent 1.98 (0.64-6.17) 0.239 1.31 (0.40-4.31) 0.656 
good 1.79 (0.83-3.84) 0.139 1.19 (0.53-2.71) 0.673 
fair 3.46 (1.68-7.11) 0.001 2.82 (1.28-6.23) 0.010 
mechanism     
PK/PD 4.66 (2.24-9.69) <0.001 3.37 (1.13-10.06) 0.030 
PK 4.03 (1.46-11.12) 0.007 2.43 (1.10-5.40) 0.028 
PD 3.36 (1.62-6.97) 0.001 2.34 (1.09-5.04) 0.030 
present additional risk factor  0.67 (0.08-5.68) 0.711 1.02 (0.09-11.12) 0.987 
OR – odds ratio; CI – confidence interval; a – odds ratio adjusted for number of drugs; risk 
rating C - Monitor therapy; risk rating D - Consider therapy modification; risk rating X - Avoid 












Table 6. Calculation of DDI-AE probability score based on LexiInteract monograph items 
 DDI-AE probability scores 
 DDI-AE 1 DDI-AE 2 
Item Points Points 
Presence of X class pDDI 2 2 
Presence of D class pDDI 3 3 
Presence of more than 2 C class pDDIs 3 3 
Severity major 3 3 
Severity moderate 1 1 
Mechanism PK/PD 3 3 
Mechanism PK 2 2 
Mechanism PD 2 2 
Number of drugs - multiplied by 1.4 
pDDI – potential drug-drug interaction; risk rating C - Monitor therapy; risk rating D - Consider 
therapy modification; risk rating X - Avoid combination; PK – pharmacokinetic; PD – 
pharmacodynamic; PK/PD – pharmacokinetic/pharmacodynamics 
 
 
Table 7. Predictive value of DDI-AE probability score 
 DDI-AE probability scores  
  
ADR caused by DDI  
(clinical panel + DIPS by Horn et 
al.) 
DDI-AE 1 DDI-AE 2 
ROC analysis    
AUC (95% CI) 0.800 (0.744-0.856) 0.811 (0.750-0.872) 
p value <0.001  <0.001 
    
 cut-off value cut-off value 
 ≥ 7 points ≥ 8 points ≥ 16 points ≥ 20 points 
Sensitivity 76.5% 64.7% 73.5% 61.8%  
Specificity 77.9% 80.4% 66.9% 83.6% 
DIPS – Drug Interaction Probability Scale; CI – confidence interval 
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
